8月15日，爱威科技大宗交易成交15万股，成交额378.15万元，占当日总成交额的6.35%，成交价25.21元，较市场收盘价26.4元折价4.51%。 | 2025-08-15 | 爱威科技 | 688067 | 25.21 378.15 15 | 国海证券股份有限 公司山东分公司 | 国联民生证券股份 有限公司北京建材 1-To researce and a brance 3-14, villabor 11 . J. ex- | | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | 卖出营业部 | ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aiwei Technology in the medical device industry, indicating a high PE ratio compared to industry averages [1][2] - As of August 11, Aiwei Technology's stock closed at 28.55 yuan, with a PE ratio of 80.59, significantly higher than the industry average of 56.56 and median of 39.76 [1][2] - The company's total market capitalization is 1.941 billion yuan, ranking it 100th in the medical device sector [1] Group 2 - For Q1 2025, Aiwei Technology reported revenue of 53.2953 million yuan, a year-on-year increase of 13.85%, and a net profit of 6.3210 million yuan, up 24.63% [2] - The company's gross profit margin stands at 55.59% [2] - As of March 31, 2025, Aiwei Technology had 3,605 shareholders, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1]

（文章来源：证券日报） 证券日报网讯 8月11日晚间，爱威科技发布公告称，公司于近日取得由挪亚检测认证集团有限公司签发 的《环境管理体系认证证书》《职业健康安全管理体系认证证书》。 ...

证券代码：688067 证券简称：爱威科技 公告编号：2025-027 爱威科技股份有限公司 关于取得环境管理体系、职业健康安全管理体系 认证证书的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、基本情况 爱威科技股份有限公司（以下简称"公司"）于近日取得由挪亚检测认证集 团有限公司签发的《环境管理体系认证证书》与《职业健康安全管理体系认证证 书》，具体情况如下： （一）环境管理体系认证证书 1、证书编号：NOA2505840 2、认证标准：GB/T24001-2016idt ISO14001:2015 3、认证范围：许可范围内尿液及其他样本分析设备、免疫分析设备、生化 分析设备、血液学分析设备、体外诊断试剂的研发、生产、销售和服务 4、有效期限：2025 年 08 月 04 日至 2028 年 08 月 03 日 （二）职业健康安全管理体系认证证书 1、证书编号：NOA2505841 2、认证标准：GB/T45001-2020idt ISO45001:2018 3、认证范围：许可范围内尿液及其他样本分 ...

Core Viewpoint - Awei Technology (688067.SH) has recently obtained the Environmental Management System Certification and the Occupational Health and Safety Management System Certification from Noah Testing Certification Group Co., Ltd, indicating compliance with national standards in these areas [1] Group 1 - The acquisition of the two certifications signifies that the company has improved its environmental management and occupational health and safety management practices [1] - The certifications enhance the company's ability to reduce environmental pollution and production safety risks [1] - The improvements in management practices are expected to further enhance the company's management capabilities and core competitiveness [1]

Company Overview - Awei Technology's closing price on August 8 was 28.98 yuan, up 7.25%, with a rolling PE ratio of 81.80, marking a new low in 861 days, and a total market capitalization of 1.971 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 55.70 and a median of 39.08, placing Awei Technology at the 101st position in the industry ranking [1] - As of the first quarter of 2025, two institutions held shares in Awei Technology, with a total of 104,200 shares valued at 0.02 million yuan [1] Business Operations - Awei Technology specializes in the research, development, production, sales, and service of medical clinical testing analysis instruments, in vitro diagnostic reagents, and medical consumables [1] - The company has a total of 259 authorized patents (including 97 domestic invention patents and 18 overseas patents) and 30 software copyrights as of December 31, 2024 [1] - The company holds 78 first-class medical device registration certificates, 72 second-class medical device registration certificates, and 4 third-class medical device registration certificates [1] - In July 2024, Awei Technology was recognized as the "Changsha Machine Vision Technology Automatic Microscope Morphological Testing Technology Innovation Center" [1] Financial Performance - In the first quarter of 2025, Awei Technology reported revenue of 53.2953 million yuan, a year-on-year increase of 13.85%, and a net profit of 6.3210 million yuan, up 24.63%, with a gross profit margin of 55.59% [1]

从董秘的年龄分布来看，40岁-50岁董秘是市场的中坚力量，占比共计达到69%；50岁以上的董秘占比为11%；40岁及以下董秘群体占比为20%。其中，目前仍任职的最年轻的男上市公司董秘年 从董秘的学历分布看，拥有本科、硕士学历的董秘占比分别为40%、60%。 从薪酬分布看，A股体外诊断公司董秘年薪平均值为77万元。经统计，处于50万以下、50万-100万、100万-200万、200万以上各区间的人数占比分别为20%、63%、14%、3%。 其中，年薪排行前三的董秘分别为新产业的张蕾、科华生物的金红英、硕世生物的胡园园，三人年薪分别为284万元、171.11万元、136.67 万元。 从薪酬变动幅度看（仅统计任职两年以上董秘薪资数据），迪瑞医疗的安国柱2024年薪酬降幅最大，同比降幅达25.82%；九强生物的王建民薪酬增幅最大，同比涨幅达172.86%。 责任编辑：公司观察 专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达4 ...

专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，统计数据显示，剔除董秘已离任公司后，A股共有35家上市体外诊断公司，其聘任总体情 况如下（部分统计口径剔除无效数据）。 从董秘的年龄分布来看，40岁-50岁董秘是市场的中坚力量，占比共计达到69%；50岁以上的董秘占比 为11%；40岁及以下董秘群体占比为20%。其中，目前仍任职的最年轻的男上市公司董秘年龄33岁，为 爱威科技的袁绘杰；最年轻的女董秘年龄为32岁，为易瑞生物的李文天。 从董秘的学历分布看，拥有本科、硕士学历的董秘占比分别为40%、60%。 从薪酬分布看，A股体外诊断公司董秘年薪平均值为77万元。经统计，处于50万以下、50万-100万、 100万-200万、200万以上各区间的人数占比分别为20%、63%、14%、3%。 其中，年薪排行前三的董秘分别为新产业的张蕾、科华生物的金红英、硕世生物的胡园园，三 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aiwei Technology, particularly its low PE ratio compared to industry averages [1][2] - As of August 7, Aiwei Technology's stock closed at 27.02 yuan, with a PE ratio of 76.27, marking a new low in 832 days and a total market capitalization of 1.837 billion yuan [1] - The average PE ratio for the medical device industry is 54.79, with a median of 37.86, positioning Aiwei Technology at 96th place within the industry [1][2] Group 2 - For Q1 2025, Aiwei Technology reported revenue of 53.2953 million yuan, reflecting a year-on-year increase of 13.85%, and a net profit of 6.3210 million yuan, up 24.63% [2] - The company's gross profit margin stands at 55.59%, indicating a strong profitability relative to its revenue [2] - As of March 31, 2025, Aiwei Technology had 3,605 shareholders, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aiwei Technology, particularly its low PE ratio compared to industry averages [1][2] - As of August 4, Aiwei Technology's stock closed at 26.19 yuan, with a PE ratio of 73.93, marking a new low in 819 days and a total market capitalization of 1.781 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 54.32 and a median of 38.11, placing Aiwei Technology at the 93rd position in the industry ranking [1][2] Group 2 - For the first quarter of 2025, Aiwei Technology reported revenue of 53.2953 million yuan, a year-on-year increase of 13.85%, and a net profit of 6.3210 million yuan, up 24.63% [2] - The company's gross profit margin stands at 55.59%, indicating a strong profitability relative to its revenue [2] - As of March 31, 2025, Aiwei Technology had 3,605 shareholders, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1]